Thomas Stratford
Directeur/Membre du Conseil chez Kyowa Kirin International Plc
Profil
Thomas Stratford is currently a Director at Kyowa Kirin International Plc.
He previously worked as a Principal at GSK Plc.
Dr. Stratford holds a doctorate degree from King's College London.
Postes actifs de Thomas Stratford
| Sociétés | Poste | Début |
|---|---|---|
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas Stratford
| Sociétés | Poste | Fin |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Formation de Thomas Stratford
| King's College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |
